An evidence review published last year raised utterly bogus fears … as explained in “Fishy Prostate News”.
Experts in prostate cancer called its conclusions clearly unjustified and counterfactual.
For example, prostate cancer expert Anthony D'Amico, M.D., of Harvard Medical School called that analysis “weak, at best”.
The authors' obviously flawed, exaggerated conclusions are contradicted by a large body of evidence … and more contradictory clinical evidence appeared soon thereafter (see “Can Prostate Cancer be Curbed by Omega-3s?”).
We listed eight reasons why experts said that the study's conclusions were misleadingly selective, and clearly unsupported by the very evidence that the authors reviewed.
Yet, the news media – which loves negative and counterintuitive news – reported the authors' truly silly conclusions uncritically.
You'll find links to research showing that omega-3s reduce prostate cancer risk – and that diets high in omega-6-rich vegetable oils (such as the standard American diet) raise the risk – in “Positive Omega-3/Prostate Trial”.
As the authors of a recent study wrote, dozens of studies show that omega-6 fatty acids stimulate prostate cancer growth while omega-3 polyunsaturated fatty acids inhibit it (Ritch CR et al. 2007).
And a new clinical trial adds more evidence that omega-3s help curb prostate cancer.
Canadian clinical study links omega-3s to slower prostate cancer growth
A clinical study from Laval University in Quebec, Canada suggests that omega-3 fish oil supplements help slow prostate cancer growth in patients with low-risk prostate cancer.
The study involved 48 men diagnosed with slow-growing, hence low-risk prostate cancers (Moreel X Xm et al. 2014).
Within six months of diagnosis of low-risk prostate cancer, all men underwent a repeat biopsy and the disease had progressed in just over one-quarter (29 percent) of the men, from a “Gleason score” of 6 to a score of 7.
At the time of the biopsy, the men's fatty acid intakes were estimated using data from a diet questionnaire, and the levels of omega-3 fatty acids in their red blood cells and prostate tissue were measured.
The Canadian team then compared the men's prostate-tissue levels of EPA – one of the two key omega-3s in fish oil – to the status of their cancers.
The results showed that the risk of prostate cancer progression was lower in patients who had higher omega-3 EPA levels in their prostate issue.
As the researchers concluded, “this initial analysis suggests that prostate tissue omega-3 fatty acids, especially EPA, may be protective against prostate cancer.” (Moreel X Xm et al. 2014)
  • Apte SA, Cavazos DA, Whelan KA, Degraffenried LA. A low dietary ratio of omega-6 to omega-3 Fatty acids may delay progression of prostate cancer. Nutr Cancer. 2013;65(4):556-62. doi: 10.1080/01635581.2013.775316.
  • Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. 2001 Aug;58(2):283-8.
  • Astorg P. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. Cancer Causes Control. 2004 May;15(4):367-86. Review.
  • Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, McHugh K. Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia. 2006 Feb;8(2):112-24.
  • Moreel X Xm, Allaire J, Léger C, Caron A, Labonté ME, Lamarche B, Julien P, Desmeules P, Têtu B, Fradet V. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prev Res (Phila). 2014 May 13. pii: canprevres.0349.2013. [Epub ahead of print]
  • Ritch CR, Wan RL, Stephens LB, Taxy JB, Huo D, Gong EM, Zagaja GP, Brendler CB. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol. 2007 Jan;177(1):97-101; discussion 101.
  • Shelton PQ, Ivanowicz AN, Wakeman CM, Rydberg MG, Norton J, Riggs SB, Teigland CM. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors. Urology. 2013 May;81(5):979-84. doi: 10.1016/j.urology.2012.10.089. Epub 2013 Mar 20.
  • Szymanski KM, Wheeler DC, Mucci LA. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr. 2010 Nov;92(5):1223-33. doi: 10.3945/ajcn.2010.29530. Epub 2010 Sep 15. Review.